SCHEMBL6481576

SCHEMBL6481576

COc1ccc(CNc2ccc3c(c2)Cc2ccccc2-3)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.59
ALDH1A1 P00352 5/20 0.59
KDM4E B2RXH2 5/20 0.59
HPGD P15428 2/20 0.59
RAB9A P51151 5/20 0.55
NPC1 O15118 4/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
LMNA P02545 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
GAA P10253 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
HIF1A Q16665 1/20 0.49
TDP1 Q9NUW8 1/20 0.48
MAPK1 P28482 1/20 0.47
FFAR1 O14842 1/20 0.47
CYP1A2 P05177 2/20 0.47
ADRA2A P08913 1/20 0.47
MAOA P21397 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6483979 0.90 MAPT (0.53) MAPTALDH1A1KDM4EHPGDRAB9A
SCHEMBL6482704 0.87 MAPT (0.67) MAPTALDH1A1KDM4EHPGDRAB9A
SCHEMBL6491260 0.84 MAOA (0.55) MAPTALDH1A1KDM4EHPGDRAB9A
SCHEMBL6135766 0.83 CA1 (0.60) MAPTALDH1A1KDM4EHPGDRAB9A
SCHEMBL6482846 0.82 MAPT (0.52) MAPTALDH1A1KDM4EHPGDRAB9A
SCHEMBL6494317 0.82 CYP1A2 (0.47) MAPTALDH1A1KDM4EHPGDRAB9A
SCHEMBL6481656 0.81 KDM4E (0.56) MAPTALDH1A1KDM4EHPGDRAB9A
SCHEMBL6483232 0.79 MEN1 (0.68) MAPTALDH1A1KDM4EHPGDRAB9A
SCHEMBL8317517 0.77 ALDH1A1 (0.73) MAPTALDH1A1KDM4ERAB9AL3MBTL1
Fluorene SCHEMBL28228753 0.77 MAPT (0.61) MAPTALDH1A1KDM4EHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 MAPT 2337/4885ALDH1A1 4486/4885KDM4E 1279/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 MAPT 3500/4885ALDH1A1 4111/4885KDM4E 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.